

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MICROPORT CARDIOFLOW MEDTECH CORPORATION

微创心通医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2160)

FORECASTED INTERIM RESULTS — DECREASE IN NET LOSS

This announcement is made by MicroPort CardioFlow Medtech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary review of the unaudited management accounts of the Group for the six months ended June 30, 2021 and an assessment of the latest information currently available to the Board, the Group is expected to record a net loss (unaudited) of approximately RMB68 million to RMB73 million for the six months ended June 30, 2021, representing a decrease of approximately 40% to 44% from that of approximately RMB122 million (unaudited) for the six months ended June 30, 2020.

The expected decrease in the net loss of the Group is mainly attributable to (i) the significant increase in revenue as a result of the significant progress the Group has made in commercializing VitaFlowTM; (ii) the significant increase in gross profit due to the effective cost control in line with the revenue growth; and (iii) the decrease in finance costs and other operating costs as certain cost items recorded in the six months ended June 30, 2020 were one-off and non-recurring in nature. As of June 30, 2021, TAVI (transcatheter aortic heart valve implantation) procedures using VitaFlowTM had been performed at over 200 hospitals in China, most of which are Class IIIA Hospitals located at tier-one and tier-two cities.

The information contained in this announcement is only based on a preliminary assessment of the consolidated management accounts and relevant revenue estimates made available to the Board as of the date of the announcement, which have not been audited or reviewed by the Company's auditors or reviewed by the audit committee of the Company, and may be subject to adjustments. The Group's consolidated results for the six months ended June 30, 2021 are expected to be published in August 2021 according to the Listing Rules.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
MicroPort CardioFlow Medtech Corporation
Luo Qiyi
Chairman

Shanghai, PRC, July 26, 2021

As of the date of this announcement, the executive Directors are Mr. Chen Guoming, Ms. Yan Luying and Mr. Wu Guojia, the non-executive Directors are Dr. Luo Qiyi, Mr. Zhang Junjie and Ms. Wu Xia, and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Jiang Hualiang and Ms. Sun Zhixiang.